Business UpdateJul 15, 2026, 08:06 AM
VivoSim Receives $5M Eli Lilly Milestone; Forecasts 500%+ FY27 Growth
AI Summary
VivoSim Labs, Inc. announced it received a $5 million milestone payment from Eli Lilly related to a former inflammatory bowel disease drug program, triggered by the first patient dosing in Phase 2 studies. The company remains eligible for up to $45 million in additional milestone payments. VivoSim also anticipates significant revenue growth of over 500% in Fiscal Year 2027, driven by increasing demand for its New Approach Methodologies (NAMs) models. The company highlighted the high predictive accuracy of its NAMkind™ Liver spheroid and Intestine models, benefiting from the FDA's encouragement of human-relevant NAMs.
Key Highlights
- Received $5 million milestone payment from Eli Lilly for a former IBD drug program.
- Payment triggered by the first patient dosing in Phase 2 studies of the drug.
- Eligible for up to $45 million in additional milestone payments from Eli Lilly.
- Anticipates over 500% revenue growth in Fiscal Year 2027.
- NAMkind™ Liver spheroid model achieved 91% predictive accuracy.
- NAMkind™ Intestine models deliver greater than 90% sensitivity and accuracy.
- FDA actively encourages human-relevant New Approach Methodologies (NAMs).
Price Impact
More from VIVS